Thank You
For Registering Your
Interest!

This clinical trial is investigating an experimental study drug (casdatifan) for people living with unresectable, locally advanced, or metastatic renal cell carcinoma with a primary clear cell component. The purpose of the study is to determine if the study drug improves patient outcomes compared to standard treatment.

This is a research study investigating a potential new medication for weight management.

This study is investigating a potential new treatment that aims to lower hypertension (blood pressure that is too high) when used alongside standard treatments.

This is a research study investigating a potential new medication for type 2 weight management.

This research study is investigating a new potential treatment for Venous Leg Ulcers (VLUs), a clear gel containing an experimental drug that is applied directly to the VLU; compared to a control placebo gel treatment.

Canopy Clinical has launched a suite of weight-management related studies. Register your interest in participating today.

Diabetic foot ulcers (DFUs) are a serious and common complication of diabetes, affecting millions of people worldwide. This study is investigating a potential topical treatment called CYWC628. The treatment aims to support wound healing by promoting tissue regeneration, reducing inflammation, and improving blood flow to the affected area.

This clinical research study is investigating a potential tropical treatment for mild to moderate toenail fungal infections (onychomycosis). Onychomycosis is a common chronic condition that causes thickening, discoloration, and damage to the toenails.

This study is investigating the effect of an investigational oral medication, which is designed to reduce pain and swelling during an acute gout flare.

Osteoarthritis (OA) is a chronic joint condition that affects millions of people worldwide, particularly older adults. This study is investigating a potential new treatment to help reduce knee pain and improve joint function in people living with OA.